Dr. Monica E. McCallum is an Assistant Professor of Chemistry in the Department of Chemistry at the University of Pennsylvania’s School of Arts & Sciences. Her research focuses on understanding the biochemical origins of natural products and their roles in microbial communication. She leads the McCallum Lab, which employs interdisciplinary approaches combining organic synthesis, biochemistry, microbiology, and microscopy to study microbial natural products in their native contexts. Education: 2016 – Postdoctoral Fellow at Harvard University under Prof. Emily P. Balskus 2016 – PhD in Organic Chemistry from Baylor University 2013 – PhD Candidate at Colorado State University 2011 – B.S. in Chemistry from University of California, Irvine Research Interests: Dr. McCallum’s work bridges organic synthesis and microbiology to decode microbial metabolite functions. Key themes include: Synthesizing complex natural products and their biosynthetic precursors Discovering novel enzyme-catalyzed reactions Unraveling microbial communication mechanisms via natural products Investigating environmental microbial community dynamics Lab & Collaborations: The McCallum Lab emphasizes interdisciplinary collaboration, integrating techniques from organic chemistry, molecular biology, and microscopy to study natural products in situ. Current projects focus on diazeniumdiolate biosynthesis pathways and enzymatic detoxification of marine toxins.
Michele Klingbeil is a Professor in the Department of Microbiology at the University of Massachusetts Amherst, where she leads the Klingbeil DNA Replication Laboratory. She received her PhD in Cell and Molecular Biology from the University of Toledo in 1996 and previously worked at Johns Hopkins School of Medicine before moving to UMass in July 2007. Her educational background includes: PhD in Cell and Molecular Biology, University of Toledo, 1996 Dr. Klingbeil's research focuses on the unique biology of trypanosomatid parasites, particularly Trypanosoma brucei , the causative agent of African sleeping sickness. Her laboratory investigates two main areas: (1) replication of the unusual mitochondrial DNA network called kinetoplast DNA (kDNA), and (2) nuclear DNA replication initiation. Her work on kDNA is particularly significant as this structure is essential for parasite survival but has no counterpart in mammalian hosts, making it an attractive drug target. She employs a combination of reverse genetics (RNAi), cell biology, and biochemistry to understand the replication and repair mechanisms of kDNA, with a special focus on a family of four DNA polymerases related to bacterial Pol I. Dr. Klingbeil's recent publications reveal her laboratory's deep investigation into mitochondrial DNA polymerases in trypanosomatids, with discoveries showing multiple polymerases having specialized functions in kDNA replication and repair. Her research has established that several of these polymerases are essential for parasite viability, opening new avenues for drug development. She has also made significant contributions to understanding the simplified Origin Recognition Complex in trypanosomatids compared to other eukaryotes. Dr. Klingbeil has received the Thomas G. Lessie Distinguished Lectureship Award for her impact on teaching at the graduate level. Her research is funded by the National Institutes of Health, U.S. Department of Agriculture, the Joeph P. Healey Endowment, and the University of Massachusetts Amherst. She has mentored numerous graduate and undergraduate students, including current PhD candidates Dave Bruhn, Jeniffer Concepción, and Juemin Luo, as well as visiting scholar Eva Vidal Rico. Her former students have gone on to positions at institutions including Dana Farber/Broad Institute, Regis College, and Flagship Ventures. The laboratory regularly participates in scientific conferences including the Molecular Parasitology Meeting at Woods Hole and the Kinetoplastid Molecular Cell Biology conference. Dr. Klingbeil teaches several courses including Parasitology (MICRO 590S), Parasitology Lab (MICRO 590L), Molecular Mechanisms of Pathogenesis (MICRO 797P), Advanced Cell Biology (MCB 641), and Writing in Microbiology (MICRO 360). Her laboratory organizes regular social events including pumpkin carving parties and outings to Six Flags New England and Mt. Sugarloaf.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
Michael Groll serves as Professor and Chair of Biochemistry at the Technical University of Munich (TUM), where he leads structural biology and enzymology research with a focus on proteasome mechanisms and inhibitor development. His laboratory, located at the Ernst-Otto-Fischer-Str. 8 campus in Garching, maintains active collaborations in drug discovery for cancer and infectious diseases. His primary research domains include proteasome inhibition, enzyme catalysis, and natural product biosynthesis, employing X-ray crystallography, biochemical assays, and bioengineering to dissect molecular mechanisms. Recent work emphasizes AI-guided enzyme optimization, bacterial stress response targeting, and structural characterization of halogenation enzymes, reflecting interdisciplinary approaches bridging chemistry and biology. Analysis of his 2023-2025 publications reveals consistent innovation in proteasome-targeted therapeutics, with 15 high-impact papers featuring structural insights into enzyme-inhibitor complexes and biosynthetic pathways. Key trends include engineering megasynthetases for immunoproteasome inhibitors, optical control of protein degradation, and elucidating metal-dependent mechanisms in antibiotic biosynthesis. No scientific awards were documented in the provided source material. While specific grant details and student mentorship records were not disclosed, his extensive publication record indicates leadership in collaborative research projects involving structural biology and chemical biology methodologies. The Chair of Biochemistry under Prof. Groll operates as a hub for structural enzymology, housing facilities for protein crystallography, enzyme kinetics, and natural product characterization. His team actively contributes to TUM's research ecosystem through partnerships with pharmaceutical groups and international structural biology consortia.
Amit R. Reddi is a Professor at the Department of Chemistry, Georgia Institute of Technology. His research focuses on metalloproteins, particularly the mechanisms of heme trafficking and redox signaling in relation to cancer, neurodegenerative disorders, and infectious diseases. He has received numerous awards for both research and teaching excellence. Education : B.A. from Carleton College (2003) Ph.D. from Columbia University (2008) NIH Postdoctoral Fellowship at Johns Hopkins University (2013) Research Interests : The Reddi laboratory investigates cellular mechanisms of metalloprotein activation and inter-biomolecular communication in metabolic and signaling pathways critical to human health. Key projects explore heme trafficking pathways and the role of Cu/Zn Superoxide Dismutase (SOD1) in redox signaling, with implications for cancer, neurodegenerative diseases, and microbial pathogenesis. Scientific Awards : Vasser Woolley Faculty Fellowship (2021) Student Recognition of Excellence in Teaching Class of 1934 Award (2021) CTL/BP Junior Faculty Excellence in Teaching Award (2019) Bergmann Memorial Award (2018) Blanchard Professorship (2016) NSF CAREER Award (2015) NIH NRSA Post-doctoral Fellowship (2008-2011) Grants & Fellowships : NSF CAREER Award (2015) Sigma Xi Grants-In-Aid-of-Research (2003) NIH Cancer Research Training Award Fellowship (1999-2001)
Prof. Johannes A. Lercher is a retired professor (as of April 2023) at the Technical University of Munich (TUM), holding the Chair of Chemical Technology II within the Department of Chemistry. His research focuses on heterogeneous catalysis, particularly understanding catalytic processes at solid-liquid and solid-gas interfaces, with applications in sustainable energy production, CO₂ conversion, and catalytic upcycling of polymers. He has held academic positions at the University of Twente (Netherlands) and the Pacific Northwest National Laboratory (USA), and has been Editor-in-Chief of the Journal of Catalysis . His honors include the Alwin Mittasch Prize (2021), ENI Award (2016), and Kozo Tanabe Prize (2013). His recent work emphasizes low-temperature polymer upcycling, methane activation, and bioinspired catalyst design, leveraging advanced spectroscopic and operando techniques. Despite retirement, his contributions to catalysis research remain impactful. Education: PhD (1980) and Habilitation (1985), Vienna University of Technology Visiting Lecturer, Yale University (1982) Research Interests: Heterogeneous catalysis, catalytic interfaces, sustainable energy carriers, CO₂ valorization, and polymer waste upcycling. Key areas include: Design of catalysts for selective hydrocarbon synthesis Mechanistic studies using advanced spectroscopy Development of scalable catalytic processes for industrial applications Recent Trends in Publications: Focus on low-temperature polymer recycling (e.g., PVC and polyolefin upcycling), methane activation via novel catalysts (e.g., Co 2+ in ZSM-5), and bioinspired catalytic strategies. His work bridges fundamental catalysis with industrial relevance, emphasizing sustainability and energy efficiency. Awards and Recognition: Member, Academia Europaea and US National Academy of Engineering Recipient of multiple international catalysis awards (see full list above) Grants and Labs: Led the Institute for Integrated Catalysis (Pacific Northwest National Lab, 2011–present). His research groups have pioneered studies on zeolite-confined reactions and interfacial catalysis, with collaborations spanning academia and industry. Labs/Teams: Active in the TUM Department of Chemistry and international networks focused on catalytic innovation for a carbon-neutral economy.
Christian Friedrich Wilhelm Becker is a full Professor at the University of Vienna, holding a position within the Faculty of Chemistry and the Department of Biological Chemistry. His research profile shows extensive activity in protein chemistry and biochemistry, with particular focus on post-translational modifications and their implications in disease mechanisms. His work bridges chemical biology, biochemistry, and biomedical applications, contributing significantly to the academic and research landscape at one of Europe's oldest and most prestigious universities. Faculty of Chemistry, University of Vienna Department of Biological Chemistry Active research leader with numerous ongoing projects Significant publication record spanning multiple disciplines Professor Becker's research primarily focuses on protein chemistry, particularly post-translational modifications and their role in protein function and dysfunction. His work spans multiple interconnected areas including ubiquitination, protein aggregation, prion protein behavior, and biomimetic approaches to protein analysis. His research has significant implications for understanding neurodegenerative diseases and developing novel therapeutic approaches. The fingerprint analysis of his work shows strong connections to biochemistry, molecular biology, and chemistry, with particular emphasis on cysteine chemistry, glycosylation, and amino acid modifications. Analysis of Professor Becker's recent publications (2021-2025) reveals a consistent research trajectory focused on protein modification techniques and their biological implications. His work shows increasing sophistication in chemical biology approaches to study protein function, with particular emphasis on ubiquitination pathways and protein aggregation mechanisms. The integration of chemical synthesis methods with biological analysis represents a hallmark of his research approach. His publications span high-impact journals in biochemistry, chemical biology, and peptide science, demonstrating the interdisciplinary nature of his contributions. Professor Becker has received notable recognition for his research contributions, most prominently the Cathay Award in 2020. This award acknowledges his significant contributions to the field of protein chemistry and chemical biology. His work appears to have practical applications in therapeutic development, particularly in the areas of targeted protein degradation and immunotherapy, which likely contributed to this recognition. Cathay Award (2020) Professor Becker leads multiple significant research projects, including 'Targeted protein degradation - from small molecules to complex organelles' (2020-2024), 'Taktira: Development of an improved, low-side-effect and sustainable immunotherapy' (2019-2023), and 'Structure Zoom: Zooming in on protein functional sites with atomic resolution' (2018-2021). These projects demonstrate substantial grant funding and collaborative research efforts across multiple institutions. His active participation in 290 recorded activities through 2025 indicates a highly engaged research program with numerous collaborators and trainees. Targeted protein degradation project (2020-2024) Taktira immunotherapy project (2019-2023) Structure Zoom project (2018-2021) Professor Becker's research environment includes a robust team of collaborators and junior researchers, as evidenced by the numerous co-authored publications and activities. His work intersects with multiple research groups studying protein function, modification, and therapeutic applications. The international collaboration network shown in his profile indicates significant engagement with researchers across multiple countries, creating a dynamic research ecosystem focused on advancing protein science and its biomedical applications.
Markus Heinonen is an Academy Research Fellow at Aalto University's Department of Computer Science within the School of Science. His academic position is tied to Harri Lähdesmäki's Professorship, focusing on probabilistic machine learning. He holds a Doctoral degree in Engineering and Technology from the University of Helsinki (2013). His research integrates probabilistic modeling , deep learning , and differential equations , with applications in computational biology, drug discovery, and biophysics. Key themes include Gaussian processes, Bayesian inference, generative models, and their use in understanding complex biological systems like immune cell behavior (e.g., T cell receptor analysis in aplastic anemia) and molecular design. He leads major projects such as the Deep Learning with Differential Equations initiative (2020–2025), exploring continuous-time models and physics-informed neural networks. His work bridges theory and application, evidenced by collaborations in diffusion models , optimal transport , and single-cell analysis . Publications span over 65 peer-reviewed outputs, with recent emphases on robust neural network training, multi-target molecular prediction, and interpretable drug design frameworks. His research contributes to UN Sustainable Development Goal 3 (Good Health) through advancements in disease modeling and therapeutic development. He has undertaken visiting research roles at the University of California, San Francisco (2017) and Telecom ParisTech (2013–2014). Media highlights include recognition for work on TCR-epitope prediction and AI-driven enzyme engineering.
Professor George Britovsek (FRSC) is a leading figure in catalysis and sustainable carbon management at Imperial College London . As Director of the MRes in Catalysis & Engineering and Head of Teaching in Inorganic Chemistry, he bridges academic leadership with cutting-edge research. His work focuses on transition metal complexes for converting ethylene , alkanes , biomass , and CO₂ into valuable chemicals and fuels through industrial collaborations. Education : M.Sc. (Technical University of Aachen, 1990), Ph.D. (Aachen, 1993) under Prof. W. Keim Postdoctoral Training : University of Tasmania (1994-1996), Imperial College London (1996-2000) His research interests span: Selective oxidation of alkanes using bio-inspired iron complexes Alkene conversions to functional polymers via novel catalysts CO₂ valorization into polymers and cyclic carbonates Biomass-derived feedstocks for chemical synthesis Recent catalysis trends highlight his work on: Designing Fe-N/C catalysts for epoxidation Developing PN3P pincer ligands for H₂ activation Creating degradable polyethylene via iron-catalyzed chain growth Modeling alternating α-olefin distributions in chromium systems Awards : Fellow of the Royal Society of Chemistry (FRSC) Students & Collaborators actively engage in: Photocatalytic polymer degradation Electrocatalytic CO₂ conversion Functionalized polymeric materials 3D-printed catalytic scaffolds His Britovsek Research Group operates at the Molecular Sciences Research Hub, White City Campus, advancing both homogeneous and heterogeneous catalysis through experimental and computational approaches.
Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.
Pim de Vink is a doctoral researcher at Eindhoven University of Technology , affiliated with the Biomedical Engineering department and Chemical Biology group. Supervised by dr. L.-G. Milroy and prof. L. Brunsveld , his work bridges supramolecular chemistry and chemical biology , focusing on host/guest chemistry for protein complex modulation. Education: B.Sc. in Chemistry (2014) from University of Amsterdam M.Sc. in Biomedical Engineering (2016) from TU/e Internship at Max Planck Institute for Molecular Physiology (2016) on gold-catalyzed synthesis Research Themes: His research develops switchable cucurbituril-based systems for light-controlled enzyme activation and artificial signaling networks. Key areas include protein-protein interaction stabilization , thermodynamic modeling , and allosteric nuclear receptor modulation . Publication Trends: Across JACS , Chemical Science , and RSC Chemical Biology , his work from 2017–2023 emphasizes supramolecular tools for biochemical applications. Notable contributions include 100-fold affinity enhancement of 14-3-3 ligands and UV-responsive cucurbituril release mechanisms . Grants: Funded by Netherlands Organization for Scientific Research (NWO) through Gravity program 024.001.035 and VICI grant 016.150.366.
Dr. John A. Copland III is a Professor of Cancer Biology and Biochemistry & Molecular Biology at Mayo Clinic in Jacksonville, Florida. He leads the Cancer Biology and Translational Research Laboratory, focusing on molecular mechanisms of carcinogenesis, tumor progression, and development of targeted cancer therapies. Education: PhD in Physiology & Endocrinology (Medical College of Georgia), MS in Endocrinology (Medical College of Georgia), BS in Chemistry (Columbus College), with postdoctoral training at University of Texas Medical Branch. Research interests center on: Identifying tumor suppressor genes (e.g., RhoB, TBR3, GATA3) and oncogenes (e.g., FOXO3a, SCD1, NPTX2). Developing patient-derived xenografts and live cell models for personalized medicine. Designing SCD1 inhibitors via in silico modeling for clinical trials. Recent publications highlight his work on SCD1 inhibition in leukemia and thyroid cancer ImmunoPET imaging of thyroid tumors CRISPR-identified drug synergies in cholangiocarcinoma Patient-specific combination therapies using xenograft models
Nancy J. Brown, M.D., is the Jean and David W. Wallace Dean of the Yale School of Medicine and holds the C.N.H. Long Professorship in Internal Medicine. Previously, she served as Chair of Vanderbilt Department of Medicine and Physician-in-Chief of Vanderbilt University Medical Center (2010–2020). Her academic career spans over three decades, with leadership roles in clinical care, research, and medical education. Education: MD, Harvard University (1986) AB in Molecular Biophysics and Biochemistry, Yale College (1981) Internship and Residency in Medicine, Vanderbilt University (1989) Fellowship in Clinical Pharmacology, Vanderbilt University (1991) Chief Resident, Vanderbilt University (1992) Research Interests: Dr. Brown’s work focuses on the renin-angiotensin-aldosterone system’s role in cardiovascular disease, hypertension, and thrombosis. Her lab has elucidated mechanisms linking aldosterone, bradykinin, and ACE inhibitors to inflammation, fibrosis, and cardiovascular risk. Current studies explore neprilysin inhibitors in heart failure and incretin-based therapies’ cardiovascular effects. Key Contributions: Identified genetic variants and African ancestry as risk factors for ACE inhibitor-associated angioedema Developed Vanderbilt’s Master of Science in Clinical Investigation program (2000) Advocated for physician-scientist development through leadership roles in NIH councils and professional organizations Recognition: Recipient of the Harriet Dustan Award, August M. Watanabe Prize, and Robert H. Williams Distinguished Chair of Medicine. Elected to the National Academy of Medicine and American Academy of Arts & Sciences. Labs/Teams: Leads the Yale School of Medicine’s cardiovascular research initiatives, focusing on translational studies of RAAS pathways and drug mechanisms.
Jonathan Conway is an Assistant Professor in the Department of Chemical and Biological Engineering at Princeton University and an associated faculty member of the High Meadows Environmental Institute (HMEI). He leads the Conway Lab, which focuses on engineering plant-microbe interactions for applications in bioagriculture, bioenergy, and biochemical industries. Education: B.S. Chemical Engineering, University of Notre Dame (2011) M.S. Chemical Engineering, North Carolina State University (2013) Ph.D. Chemical Engineering, North Carolina State University (2017) Postdoctoral Fellow, University of North Carolina Chapel Hill & Howard Hughes Medical Institute (2017-2021) Research Interests: The Conway Lab develops genetic engineering approaches for non-model bacteria at plant-microbe interfaces. Key research areas include: chemical signaling between plants and microbes, microbiome impacts on plant immunity, environmental stress responses in agricultural systems, and enzymatic degradation of lignocellulosic biomass using thermophilic bacteria. The lab employs bacterial genetics, systems biology, and biomolecular engineering to create technologies for sustainable bioindustries. Publication Trends: Recent work demonstrates strong emphasis on molecular mechanisms of plant-microbe communication (2020-2024), enzyme characterization in biomass degradation (2024-2025), and development of synthetic microbial communities for climate resilience (2024). Earlier research focused on extremophile enzymology and metabolic engineering (2012-2019). Student Advising: Currently mentors 4 graduate students and 8 undergraduates. Alumni include 9 former advisees who graduated between 2022-2024. The lab actively recruits students through Princeton's Chemical Engineering graduate program and undergraduate research initiatives. Laboratory: The Conway Lab develops microfluidic systems for root microbiome studies and genetic tools for engineering plant-associated bacteria. Current projects include designing thermophilic microbial consortia for consolidated bioprocessing and characterizing bacterial immune evasion strategies.
Professor Thomas Meier is a Visiting Professor at the Department of Life Sciences, Imperial College London (since 2015), and Director of the Centre for Structural Biology (2017–2021). He leads research on ATP synthase structure, drug targets for tuberculosis, and molecular mechanisms of disease. Previously, he was a Group Leader at the Max-Planck-Institute of Biophysics (2006–2015) and ETH Zurich's Institute of Microbiology. His work combines structural biology (X-ray crystallography, electron microscopy) with biochemical studies. Education: Dr. sc. nat. (2002) and Dipl. sc. nat. (1998) from ETH Zurich. Awards include the Wellcome Trust Investigator (2015–present). Research focuses on ATP synthase's role in energy conversion, drug development, and structural biology. His lab includes postdocs and students like Lisa Uhrig and Anthony Cheuk. Key affiliations: Centre for Structural Biology, Membrane Biology Group, and Bacterial Pathogenesis studies. Languages: German, English, French (fluent), Latin (read/write). Publications span structural biology, planetary science, and drug discovery. His work on ATP synthase inhibitors for TB has clinical implications, while astrophysical studies explore planetary formation via giant impacts.
